Eisai will pull obesity drug Belviq off U.S. shelves after FDA flags cancer risks

Eisai acquired sole rights to Belviq in a cash sale with Arena in 2017. (Eisai)

When Eisai picked up struggling obesity med Belviq in 2016, it knew it would have its work cut out for it in a chronically underperforming market. But now, after years of struggle, the drug's journey may be at an end. 

At the FDA's request, Eisai will pull Belviq and Belviq XR off U.S. shelves. The move comes after the FDA flagged a higher rate of cancer diagnoses in patients treated with the drug as part of a postmarket study evaluating cardiovascular risks. 

In January, the administration warned consumers that a more-than-four-year study, requested after Belviq's approval in 2012, showed a possible link to increased cancer risks in patients with either an established cardiovascular disease or multiple risk factors. 

Watch the Free Webinar

Chemistry Through Biology: Translating Molecular Biology Technologies into Practical Processes for API Production

Learn about the key advances and critical hurdles in transforming emerging molecular biology technologies into practical applications with commercially viable processes.

In that study, dubbed Camellia-Timi-61, 7.7% of trial patients treated with Belviq were diagnosed with cancer compared with 7.1% of patients in the placebo arm. The FDA requested Eisai pull the drug, arguing the "risks of (Belviq) outweigh its benefits based on our completed review of results from a randomized clinical trial assessing safety."

Eisai is currently in discussions with global distributors to facilitate the withdrawal, the drugmaker said in a statement Thursday.

RELATED: Eisai obesity drug Belviq may have an edge with new heart-safety data—but to what end?

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.